Haleon results re Eroxon27 Feb 2025 09:30
Full year results announcement
Twelve months ended 31 December 2024
8
Digestive Health and Other (18% of 2024 revenue)
Digestive Health and Other revenue declined 7.2% to £2.0bn which included a (9.8)% impact from net
M&A and (2.9)% from foreign exchange movements. For the year, organic revenue increased 5.5% and
Q4 24 organic revenue increased 6.6%. In 2024, Digestive Health delivered mid-single digit organic
growth which was underpinned by strength in Tums and ENO driven by innovation including Tums Chewy
Bites and ENO Chewy Bites. Elsewhere, Nexium declined as a result of weak market Towards the end of the year,
we commercialised Eroxon in the US, the first FDA-approved topical erectile dysfunction (ED) treatment
for OTC use. This launch is a new brand in a new category, therefore we expect it will take time to build
consumer awareness and education.